Publications by authors named "Funda Meric-Bernstam"

100Publications

Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials.

ESMO Open 2020 Nov;5(6)

Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/esmoopen-2020-001073DOI Listing
November 2020

Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers.

Cancer 2020 Oct 29. Epub 2020 Oct 29.

Department of Investigational Cancer Therapeutics (Phase 1 Clinical Trials Program), Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.33242DOI Listing
October 2020

KRAS Inhibition with Sotorasib in Advanced Solid Tumors.

N Engl J Med 2020 09 20;383(13):1207-1217. Epub 2020 Sep 20.

From the Department of Investigational Cancer Therapeutics, Phase I Clinical Trials Program, University of Texas M.D. Anderson Cancer Center, Houston (D.S.H., F.M.-B.); the Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte (M.G.F.), the University of California, San Francisco, San Francisco (P.N.M.), and Amgen, Thousand Oaks (H.H., J.N., G.N., J.K., B.E.H., J.C., J.R.L., G.F.) - all in California; Duke University Medical Center, Durham, NC (J.H.S.); Royal Melbourne Hospital/Peter MacCallum Cancer Centre, Melbourne, VIC (J.D.), Queen Elizabeth Hospital and University of Adelaide, Woodville South, SA (T.J.P.), and Scientia Clinical Research, Randwick, NSW (J.C. Kuo) - all in Australia; the Department of Medicine, Division of Hematology/Oncology, Indiana University School of Medicine, Indianapolis (G.A.D.); Dana-Farber Cancer Institute, Harvard Medical School, Boston (G.I.S.); the Sarah Cannon Research Institute at HealthONE, Denver (G.S.F.); Princess Margaret Cancer Centre, University Health Network, Toronto (A.S.); Fox Chase Cancer Center, Philadelphia (C.S.D.); the University of Pittsburgh Medical Center Hillman Cancer Center, University of Pittsburgh, Pittsburgh (T.F.B.); Seoul National University College of Medicine (Y.-J.B.), Samsung Medical Center, Sungkyunkwan University School of Medicine (K.P.), and the Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine (T.W.K.) - all in Seoul, South Korea; Roswell Park Cancer Institute, Buffalo (G.K.D.), and Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine, New York (P.L., B.T.L.) - all in New York; the University of Michigan, Ann Arbor (J.C. Krauss); the Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan (Y.K.); the Department of Medicine, Division of Oncology, University of Washington, Seattle (A.L.C.); Aix Marseille University, Centre National de la Recherche Scientifique, INSERM, Centre de Recherche en Cancérologie de Marseille, Assistance Publique-Hôpitaux de Marseille, Marseille, France (F.B.); Winship Cancer Institute of Emory University, Atlanta (S.S.R.); and the Alvin J. Siteman Cancer Center at Washington University School of Medicine, St. Louis (R.G.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1917239DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7571518PMC
September 2020

Rate of change in investigational treatment options: An analysis of reports from a large precision oncology decision support effort.

Int J Med Inform 2020 Nov 24;143:104261. Epub 2020 Aug 24.

The University of Texas School of Biomedical Informatics, Houston, TX, USA; Division of General Internal Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, TX, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijmedinf.2020.104261DOI Listing
November 2020

COVID-19 Pandemic and Surgical Oncology: Preserving the Academic Mission.

Ann Surg Oncol 2020 Aug 29;27(8):2591-2599. Epub 2020 May 29.

Division of Surgical Oncology, Department of Surgery, Massachusetts General Hospital and Harvard Medical School, 55 Fruit St., Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1245/s10434-020-08563-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7257352PMC
August 2020

Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss.

Oncotarget 2020 Mar 17;11(11):969-981. Epub 2020 Mar 17.

Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.27503DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7082117PMC
March 2020

Antibody-Drug Conjugates: Patient and Treatment Selection.

Am Soc Clin Oncol Educ Book 2020 Mar;40:1-10

Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_280775DOI Listing
March 2020

State-of-the-Art Strategies for Targeting -Dependent Cancers.

J Clin Oncol 2020 Apr 21;38(11):1209-1221. Epub 2020 Feb 21.

Department of Investigational Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.19.02551DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7145587PMC
April 2020

Somatic genetic aberrations in gallbladder cancer: comparison between Chinese and US patients.

Hepatobiliary Surg Nutr 2019 Dec;8(6):604-614

National Cancer Center/National Clinical Research Center for Cancer/Department of Pancreatic and Gastric Surgery, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College/National Cancer Center/National Clinical Research Center for Cancer/Department of Hepatobiliary and Pancreatic Surgery, Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen 518116, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/hbsn.2019.04.11DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6943012PMC
December 2019

Correction: FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells.

Oncotarget 2019 Dec 10;10(65):7014-7015. Epub 2019 Dec 10.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.27353DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6916757PMC
December 2019

Targeting AKT for cancer therapy.

Expert Opin Investig Drugs 2019 Nov 12;28(11):977-988. Epub 2019 Oct 12.

Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, UT MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13543784.2019.1676726DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901085PMC
November 2019

Exposure to anti-PD-1 causes functional differences in tumor-infiltrating lymphocytes in rare solid tumors.

Eur J Immunol 2019 12 30;49(12):2245-2251. Epub 2019 Sep 30.

Department of Investigational Therapeutics, The University of Texas MDACC, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/eji.201948217DOI Listing
December 2019

Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion.

Eur J Cancer 2019 10 4;120:54-64. Epub 2019 Sep 4.

GEICAM (Grupo GEICAM de Investigación en Cáncer de Mama), Madrid, Spain; Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Spain; IMIM Hospital del Mar Medical Research Institute; Barcelona, Spain; Medical Oncology Department Hospital del Mar, Barcelona, Barcelona, Spain; Universitat Pompeu Fabra, Barcelona, Spain. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.07.003DOI Listing
October 2019

TAK228 enhances antitumor activity of eribulin in triple negative breast cancer.

Oncotarget 2019 Aug 20;10(49):5011-5019. Epub 2019 Aug 20.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.27082DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6707945PMC
August 2019

Next-generation sequencing for the general cancer patient.

Clin Adv Hematol Oncol 2019 Aug;17(8):447-454

The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739831PMC
August 2019

HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features.

Hum Pathol 2019 10 24;92:32-38. Epub 2019 Jul 24.

Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.humpath.2019.07.006DOI Listing
October 2019

Molecular Profiling of Tumor Tissue and Plasma Cell-Free DNA from Patients with Non-Langerhans Cell Histiocytosis.

Mol Cancer Ther 2019 06 23;18(6):1149-1157. Epub 2019 Apr 23.

Center for Personalized Cancer Therapy, Division of Blood and Marrow Transplantation, Division of Hematology/Oncology, Department of Medicine, University of California San Diego, Moores Cancer Center, La Jolla, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-18-1244DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548628PMC
June 2019

Integrated transcriptomic-genomic tool Texomer profiles cancer tissues.

Nat Methods 2019 05 15;16(5):401-404. Epub 2019 Apr 15.

Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41592-019-0388-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337246PMC
May 2019

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018).

Authors:
Sneha Berry Nicolas Giraldo Peter Nguyen Benjamin Green Haiying Xu Aleksandra Ogurtsova Abha Soni Farah Succaria Daphne Wang Charles Roberts Julie Stein Elizabeth Engle Drew Pardoll Robert Anders Tricia Cottrell Janis M Taube Ben Tran Mark Voskoboynik James Kuo Yung-Lue Bang Hyun-Cheo Chung Myung-Ju Ahn Sang-We Kim Ayesh Perera Daniel Freeman Ikbel Achour Raffaella Faggioni Feng Xiao Charles Ferte Charlotte Lemech Funda Meric-Bernstam Theresa Werner Stephen Hodi Wells Messersmith Nancy Lewis Craig Talluto Mirek Dostalek Aiyang Tao Sarah McWhirter Damian Trujillo Jason Luke Chunxiao Xu BoMarelli Jin Qi Guozhong Qin Huakui Yu Molly Jenkins Kin-Ming Lo Joern-Peter Halle Yan Lan Matthew Taylor Nicholas Vogelzang Allen Cohn Daniel Stepan Robert Shumaker Corina Dutcus Matthew Guo Emmett Schmidt Drew Rasco Marcia Brose Nicholas Vogelzang Christopher Di Simone Sharad Jain Donald Richards Carlos Encarnacion Drew Rasco Robert Shumaker Corina Dutcus Daniel Stepan Matthew Guo Emmett Schmidt Matthew Taylor Nicholas Vogelzang Carlos Encarnacion Allen Cohn Christopher Di Simone Drew Rasco Donald Richards Matthew Taylor Corina Dutcus Daniel Stepan Robert Shumaker Matthew Guo Emmett Schmidt James Mier Jeongshin An Yeun-Yeoul Yang Won-Hee Lee Jinho Yang Jong-Kyu Kim Hyun Goo Kim Se Hyun Paek Jun Woo Lee Joohyun Woo Jong Bin Kim Hyungju Kwon Woosung Lim Nam Sun Paik Yoon-Keun Kim Byung-In Moon Filip Janku David Tan Juan Martin-Liberal Shunji Takahashi Ravit Geva Ayca Gucalp Xueying Chen Kulandayan Subramanian Jennifer Mataraza Jennifer Wheler Philippe Bedard

J Immunother Cancer 2019 Feb 13;7(1):46. Epub 2019 Feb 13.

Princess Margaret Cancer Centre, Toronto, ON, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40425-019-0519-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6373015PMC
February 2019

FGFR1β is a driver isoform of FGFR1 alternative splicing in breast cancer cells.

Oncotarget 2019 Jan 1;10(1):30-44. Epub 2019 Jan 1.

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://www.oncotarget.com/fulltext/26530
Publisher Site
http://dx.doi.org/10.18632/oncotarget.26530DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343755PMC
January 2019

Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center.

JCO Clin Cancer Inform 2018 12;2:1-14

Goldy C. George, Adrianna Buford, Kenneth Hess, Sarina A. Piha-Paul, Ralph Zinner, Vivek Subbiah, Christina Hinojosa, Charles S. Cleeland, Funda Meric-Bernstam, and David S. Hong, The University of Texas MD Anderson Cancer Center; and Elmer V. Bernstam, The University of Texas School of Biomedical Informatics, Houston, TX.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/CCI.17.00030DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874009PMC
December 2018

MK-2206 window of opportunity study in breast cancer.

Ann Transl Med 2018 Nov;6(Suppl 1):S57

Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2018.10.32DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6291614PMC
November 2018

Identification of Incidental Germline Mutations in Patients With Advanced Solid Tumors Who Underwent Cell-Free Circulating Tumor DNA Sequencing.

J Clin Oncol 2018 Oct 19:JCO1800328. Epub 2018 Oct 19.

Thomas P. Slavin, Kar Wing Kevin Tsang, Susan L. Neuhausen, Stacy W. Gray, and Jeffrey N. Weitzel, City of Hope, Duarte; Kimberly C. Banks, Darya Chudova, Justin I. Odegaard, Rebecca J. Nagy, Christine E. Lee, and Richard B. Lanman, Guardant Health, Redwood City; Razelle Kurzrock, University of California, San Diego, Moores Cancer Center, San Diego, CA; Geoffrey R. Oxnard, Dana-Farber Cancer Institute; Aditya Bardia, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA; Massimo Cristofanilli, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Angel A. Rodriguez, Houston Methodist Hospital; Funda Meric-Bernstam, The University of Texas MD Anderson Cancer Center, Houston, TX; Brian Leyland-Jones, Avera Cancer Institute, Sioux Falls, SD; Mike F. Janicek, Arizona Oncology Associates Gynecology Oncology, Scottsdale, AZ; Michael Lilly, Medical University of South Carolina, Charleston, SC; and Guru Sonpavde, The University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.00328
Publisher Site
http://dx.doi.org/10.1200/JCO.18.00328DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286162PMC
October 2018

Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic.

Oncotarget 2018 Sep 4;9(69):33232-33243. Epub 2018 Sep 4.

Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.18632/oncotarget.26075DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6145698PMC
September 2018

Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy.

Expert Opin Investig Drugs 2018 09 21;27(9):741-751. Epub 2018 Aug 21.

a Department of Investigational Cancer Therapeutics , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/13543784.2018.1
Publisher Site
http://dx.doi.org/10.1080/13543784.2018.1511700DOI Listing
September 2018

Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor.

J Cutan Pathol 2018 Oct 3;45(10):786-790. Epub 2018 Aug 3.

Department of Pathology, Section of Dermatopathology, MD Anderson Cancer Center, The University of Texas, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cup.13319DOI Listing
October 2018

Reply to J.J. Tao et al.

J Clin Oncol 2018 08 1;36(23):2451. Epub 2018 Jun 1.

John D. Hainsworth, Sarah Cannon Research Institute; Tennessee Oncology, PLLC, Nashville, TN; Funda Meric-Bernstam, The University of Texas MD Anderson Cancer Center, Houston, TX; Charles Swanton, Francis Crick Institute, London, United Kingdom; Herbert Hurwitz, Duke University Medical Center, Durham, NC; Genentech, South San Francisco, CA; David R. Spigel, Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN; Christopher Sweeney, Dana-Farber Cancer Institute; Harvard Medical School, Boston, MA; Howard Burris, Sarah Cannon Research Institute; Tennessee Oncology, PLLC, Nashville, TN; Ron Bose, Washington University School of Medicine, St Louis, MO; Bongin Yoo, Alisha Stein, and Mary Beattie, Genentech, South San Francisco, CA; and Razelle Kurzrock, Moores Cancer Center, University of California, San Diego, San Diego, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2018.78.6392DOI Listing
August 2018

Evaluation of cMET aberration by immunohistochemistry and fluorescence in situ hybridization (FISH) in triple negative breast cancers.

Ann Diagn Pathol 2018 Aug 3;35:69-76. Epub 2018 May 3.

Department of Pathology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX 77030, USA; Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.anndiagpath.2018.04.004DOI Listing
August 2018

Challenges with biomarkers in cancer drug discovery and development.

Expert Opin Drug Discov 2018 08 24;13(8):685-690. Epub 2018 May 24.

a Department of Investigational Cancer Therapeutics (Phase I Program) , The University of Texas MD Anderson Cancer Center , Houston , Texas , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17460441.2018.1479740DOI Listing
August 2018

Cancer driver mutation prediction through Bayesian integration of multi-omic data.

PLoS One 2018 8;13(5):e0196939. Epub 2018 May 8.

Department of Bioinformatics and Computational Biology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0196939PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5940219PMC
August 2018

Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers.

Mol Cancer Ther 2018 07 13;17(7):1595-1601. Epub 2018 Apr 13.

Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-17-1107DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6310221PMC
July 2018